Embed Size (px)
DESCRIPTION
The Annual 7th Pharmaceutical Regulatory Asia conference is taking place this 26-29 August 2014 at the Parkroyal on Beach Road hotel, Singapore. A must attend event if you would like to get the latest updates and best practices in the pharma regulatory landscape in Asia! What’s New in 2014?: • Regulator address from the Shanghai FDA and Philippines FDA • Hear practical experience in bridging studies and waivers in Asia • Develop a global regulatory strategy towards effective product registrations • Get guidance and perspectives on the post approval variations of Active Pharmaceutical Ingredients (API) More case studies for you to learn from! • Hear OTC regulatory framework and its success stories • Innovative Fixed Dose Combination products opportunities and challenges faced • Key strategy and considerations when developing orphan drugs in Asia • Unravel the complex Indian regulatory environment and get generics marketing authorizations • Clear confusion on Japan’s biosimilars regulatory landscape and know what is needed to enter Japan • Develop a global regulatory strategy for effective product registration
Citation preview
Produced by:
International Marketing Partner:
Media Partners:
www.pharmaconasia.com
LifeSciences
IBCLIFE SCIENCES
PARKROYAL onBeach Road,
Singapore
26-29 August 2014
Part of:
Special Regulator Address from:• Shanghai FDA• Philippines FDA• National Pharmaceutical Control Bureau,
MalaysiaAttain critical insights into China’s drugregulatory system and the recent biosimilarsguidelinesMeet and network with regulatory professionalsfrom MNCs including Takeda, Baxter, ReckittBenckiser, AstraZeneca, Daiichi Sankyo, Bayer,Pfizer and more!Learn from real regulatory case experiences andsuccessfully overcome similar challenges facedGain faster market access by understanding theregulatory approval pathways, trends andexpectations in Asia
2014 Speakers Faculty Includes: Reasons Why YouCan’t Afford toMiss this Event!5
Michel MikhailChief Regulatory Officer, Executive Vice President, Global Regulatory Affairs,Fresenius Kabi, Germany, Member, Executive Committee and Board,European Generic Medicines Association (EGA)
Joy ChenDirector, Regulatory Affairs,Reckitt Benckiser,Singapore
Ariel ValenciaDeputy Director,Food & Drugs Administration,
Department of Health,Philippines
Lejun PangSenior Researcher,Shanghai Institute for
Food and Drug Safety,
Shanghai FDA, China
Stefano AccorsiDirector, InternationalRegulatory Affairs, GlobalRegulatory Affairs,Chiesi Farmaceutici, Italy
1
2
3
4
5
Pre-Conference Workshop: 26 August 2014 • 0900 – 1700
Preparing and Submitting Dossiers for Generic andBiosimilar Drug Approval
Post-Conference Workshop: 29 August 2014 • 0900 – 1700
Medical Device/ Drug DeviceCombination Product Regulationsin Europe and Asia
8:00 Morning Coffee & Registration Opens
8:50 Welcome Address from IBC Asia & Ice Breaker
9:00 Chairperson’s Opening RemarksPremath Shenoy, Regulatory Affairs Director, AstraZeneca,India
Asia Pharmaceutical MarketOutlook & Regulatory Updates
9:10 Asia Pharmaceutical Investment Opportunities &Development• Where is the Asian pharmaceutical market heading towards?• What are the investment and market opportunities available in
Asia?• How are pharma companies in Asia coping with intensifying
competition and investment from overseas?• Selecting the best business model, communication and operations
to maximize market share in Asia• How regional integration has affected product launch and
marketing in the prescription and non-prescription marketJun Bao, Senior Vice President & Chief Business Officer,Shenogen Pharma Group, ChinaBilly Sarvanantham Urudr, Chief Commercial Officer,CCM Pharmaceuticals Sdn Bhd, MalaysiaDr. Narendra Vutla, Executive Vice President & Head, R&D –Wellness, Oral Health & Site Operations, GSK ConsumerHealthcare, IndiaCarl Firth, CEO, Aslan Pharmaceuticals, Singapore
10:00 Asia’s Evolving Regulatory Landscape & Development• Current initiatives and regulatory trends in Southeast Asia• International models, frameworks and standards for Asia to adopt• Regulatory trends and their impact on R&D investment• Recent pharma marketing regulations changes, expected new
guidelines and compliance process under AEC• Are pharma companies ready for the implementation and the
liberalization of health care services?• Current regulatory challenges faced and how they can be tackled• ASEAN harmonization and to what extent will it drive Asian
innovation?Ariel Valencia, Deputy Director, Food & DrugsAdministration, Department of Health, PhilippinesKoichi Miyazaki, Senior Director, Regulatory Affairs Group, AsiaDevelopment Department, Daiichi Sankyo, JapanJoy Chen, Director, Regulatory Affairs, Reckitt Benckiser,Singapore
10:40 Morning Networking & Refreshment Break
Regulatory Pathways & Challenges
11:30 Gaining a Successful Regulatory Entry into Malaysia• Recent key updates on Malaysia’s drug registration guidelines• Updates and key points in Malaysiaís variation guidelines• What to expect and what to prepare for when seeking approval
in Malaysia• Current and future initiatives of the National Pharmaceutical
Control BureauNoorizam Ibrahim, Deputy Director, National PharmaceuticalControl Bureau, Ministry of Health, Malaysia
12:00 China’s Regulatory Updates, Pathways & Expectations• Key regulatory updates from China• Interpreting the recent biosimilars regulatory guideline• Challenges when seeking approvals in China and how to overcome
them• Regulators expectations when evaluating dossier submission in
ChinaLejun Pang, Senior Researcher, Shanghai Institute for Foodand Drug Safety, Shanghai FDA, China
12:30 Practical Difficulties in Filing for New Drug Application(NDA) in Asia• Clarifying the differences in regulations in ASEAN• To what extent is ASEAN harmonization easing the drug registration
process?• Transparency, timelines and dossier requirements and the
challenges faced• Strategies for a smooth NDA filing in AsiaShun Jin, Asia Regulatory Affairs Head, TakedaPharmaceuticals, SingaporeFinny Liu, Associate Director, Pharma Technical Regulatory,APAC Regional Hub, Roche Singapore Technical Operations,Singapore
REGISTER TODAY! +65 6508 2401 [email protected] www.pharmaconasia.com
CONFERENCE DAY ONE
27 August 2014Wednesday
VIS
ION
AR
Y K
EY
NO
TE
PA
NE
L D
ISC
US
SIO
N
13:00 Speed Networking13:10 Networking Lunch
Have the chance to have an informal chat with VIP guests during thenetworking lunch break
1 Victoria Elegant, Vice President, Medical and RegulatoryAffairs, Asia Pacific, Baxter Healthcare, China
2 Lejun Pang, Senior Researcher, Shanghai Institute forFood and Drug Safety, Shanghai FDA, China
Regulatory Considerations for Clinical Development
14:00 Conducting Multi Regional Clinical Trials (MRCT) for GlobalDrug Development• MRCTs as a solution to drug lag in Japan• Tips in management of MRCTs in which Japan participates• Optimal development strategy in Asia• Consideration of differences in intrinsic and extrinsic ethnic factors• Effectively and efficiently managing MRCTs in AsiaKoichi Miyazaki, Senior Director, Regulatory Affairs Group, AsiaDevelopment Department, Daiichi Sankyo, Japan
14:30 Practical Experience in Bridging Studies and Waivers inAsia• Overview of the different routes and possibilities of bridging
studies and waivers in Asia• What strategy was used in seeking bridging studies and waivers
approvals• Difficulties faced and how they were tackled when seeking bridging
waivers in Asia• Questions received from health authorities when seeking approvals
on waiversStefano Accorsi, Director, International Regulatory Affairs,Global Regulatory Affairs, Chiesi Farmaceutici, Italy
15:00 Afternoon Networking & Refreshment Break
Dossier Submission Best Practices
15:30 Regulatory Approach to Dossier Life Cycle Managementin Emerging Markets• Approaches in efficiently and effectively managing dossier life
cycle management• Getting support for dossier life cycle management• Regulatory outsourcing of dossier managementKevin O’Connell, Head of Dossier Management, GlobalRegulatory Affairs, UCB Pharma, Belgium
16:00 E-regulatory Affairs and eCTD Dossier Submission BestPractices• eCTD submission procedures and requirements in China ;• GIO (Global Integrated Operations) publishing model for Asia
submissions publishing which covers 17 countries;• Automate manual tasks (building dossier structures, formatting)
by developing plug-ins of Excel and AcrobatAndy Li, Publishing Team Manager, Pfizer, China
16:30 Leading Publishing Strategy Innovating Japan RegulatorySubmissions• Japan’s Submission Overview• Japan New Drug Application – eCTD filing and publishing• “eVolume” projects ñ transformed paper publishing and printing
strategyBruce Sun, Publishing Manager, Pfizer, China
17:00 Interactive Round Table Discussions1. Pharmaceutical and Biologics Regulations and
Registration in India Bobby George, Vice President Regulatory Affairs, Reliance
Life Sciences, India___________________________________________________________________________________________________________________
2. Quality by Design (QbD) & Question based Review (QbR)Considerations for New Drug DevelopmentPremnath Shenoy, Regulatory Affairs Director, AstraZeneca,India
___________________________________________________________________________________________________________________
3. Adapting to Different CTD Formats EfficientlyKevin O’Connell, Head of Dossier Management, GlobalRegulatory Affairs, UCB Pharma, Belgium
17:45 Chairperson’s Closing Remarks &End of Conference Day One
VIP
LU
NC
HT
AB
LE
S
KE
YN
OT
EP
AN
EL
DIS
CU
SS
ION
9:00 Chairperson’s Opening Remarks
Greg Torre, VP of Regulatory Strategy Worldwide, Pfizer, USAMahashabde Anu, Regional Regulatory Lead, APAC, Pfizer,USA
Regulatory Strategy for Product Development
9:10 Asia OTC Regulatory Strategy Development• OTC regulatory framework in Asia Pacific• ASEAN pharmaceutical harmonization and its implication to OTC
development• OTC innovation registration in Asia• Success story in OTC regulatory strategy factorsNoppadon (Nhum) Adjimatera, South East Asia RegionalRegulatory & Medical Director, Reckitt Benckiser, Thailand
9:50 Getting Approvals for Fixed Dose Combination (FDC)
Products in Asia• Understanding the regulations and requirements for FDC drugs
in Asia• Regulatory strategies in launching an FDC drug in Asia• Challenges and opportunities for establishing bioequivalence in
FDC drugs• Opportunities and key elements for a successful FDC developmentMay Wei, Global Regulatory Strategist, Bayer, China
10:30 Morning Networking & Refreshment Break
11:00 Regulatory Strategy and Considerations for Orphan Drug
Development in Asia• Key orphan drug regulations in Asia• When, where and how to apply for orphan drug approvals• Overcoming the various orphan drug regulatory challenges• Risk evaluation and mitigation strategies and requirementsWoody Tan, Director, Regulatory Affairs (Japan & Asia Pacific),Genzyme-Sanofi, Singapore
11:40 Obtaining Marketing Authorization for Generics in India• Overview of Generics in India• Regulatory pathway for obtaining a marketing authorization in
India• Are Bioequivalence studies required?• Selection of reference compound• Common challenges and how to overcome themBobby George, Vice President Regulatory Affairs, Reliance Life
Sciences, India
12:20 Networking Lunch
13:40 Biosimilars Development and Regulation in Japan• Updates and overview of the regulatory requirements for biosimilar
development in Japan• Development strategy for biosimilars in Japan• Tips in establishing similarity of biosimilars• Points to be considered for market authorization in JapanSatoshi Koike, Director, Regulatory Affairs, Amgen Astellas
Biopharma, Japan
REGISTER TODAY! +65 6508 2401 [email protected] www.pharmaconasia.com
CONFERENCE DAY TWO
28 August 2014Thursday
Crafting a Regulatory Strategy
14:20 Developing a Global Regulatory Strategy Towards Effective
Product Registration• Global regulatory initiatives and landscape• Unique challenges in both matured and emerging markets• Key considerations when developing and implementing global
regulatory strategies for global market access• Improve efficiency and ease of working with global regulatory
teams
May Wei, Global Regulatory Strategist, Bayer, China
Mahashabde Anu, Regional Regulatory Lead, APAC, Pfizer,USA
Michel Mikhail, Chief Regulatory Officer, Executive Vice President,Global Regulatory Affairs, Fresenius Kabi,Member, Executive Committee and Board, European Generic
Medicines Association (EGA), Germany
15:10 Afternoon Networking & Refreshment Break
Post Approval Variations
15:40 Guidance and Industry Perspectives on Post Approval
Variations of Active Pharmaceutical Ingredients (API)• Impact and hurdles of the draft ASEAN variations guidelines and
ASEAN stability guideline• Spell out (ACTD) as a challenge to regulators• Sharing of common questions asked by regulators and practical
difficulties when filing variations• Bioequivalence studies and waivers
Michel Mikhail, Chief Regulatory Officer, Executive Vice President,Global Regulatory Affairs, Fresenius Kabi, Member, ExecutiveCommittee and Board, European Generic Medicines
Association (EGA), Germany
Arvind Mishra, Joint President-Corporate QC/QA andRegulatory Affairs, Cadilla Pharmaceutical, India
International Regulatory Models & Best Practices
16:30 US FDA Current Priorities and Initiatives• Overview of the current US FDA regulations and registration
procedures• Post approval variations and stability testing requirements in US• Proving bioequivalence in the US: How and what is required?• Future initiatives and areas of focus of the US FDADuu-Gong Wu, Director of Regulatory Consulting, PPD, former
US FDA Deputy Director, USA
17:10 Chairperson’s Summary of the Day & End of Conference
PA
NE
L D
ISC
US
SIO
N
“The Asia-Pacific region will be the single largestcontributor to global pharmaceutical market growth,accounting for approximately 46% of value growththrough 2015.”~ Pharmafocus, 2012
PA
NE
L D
ISC
US
SIO
N
REGISTER TODAY! +65 6508 2401 [email protected] www.pharmaconasia.com
WORKSHOPSPRE-CONFERENCE WORKSHOP • 26 AUGUST 2014, TUESDAY (0900-1700)
Medical Device / Drug Device Combination ProductRegulations in Europe and AsiaThis interactive workshop uses case studies, group discussions and presentations to illustrate to participants the critical aspects and key insightsin getting a successful device registration in Europe and Asia. This workshop is suited for participants who are currently dealing with or areentering the medical device and combination products market in Europe and Asia.
Topics to be Discussed Include:Understanding and interpreting the recent regulatory updates and expectation from the EU and AsiaSuccess strategies in market access and registering medical devices and combination products in EU and AsiaClarifying challenges in product classificationHow is Asia/ASEAN adopting to EU medical device standards?Post marketing surveillance for medical devices/combination productsFuture initiatives and trends of medical device/combination products regulations
Prof. Jack Wong, Director, Regulatory Affairs,Terumo BCT, Secretariat in Asian HarmonizationWorking Party (AHWP) and Founder of AsiaRegulatory Professional Association (ARPA),Singapore
Duu-Gong Wu, Director of Regulatory Consulting, PPD, former US FDA Deputy Director, USA
POST-CONFERENCE WORKSHOP • 29 AUGUST 2014, FRIDAY (0900-1700)
Preparing and Submitting Dossiers for Generic andBiosimilar Drug ApprovalThis workshop is a practical and interactive session and guide for dossier preparation to achieve successful registrations. The purpose of theworkshop is to give participants a better understanding of the intricacies of dossier requirements and benefit from an industry perspectivein preparing and submitting dossiers for both generics and biosimilar registration with a focus on US FDA dossier submission requirementsfor a wider view on what is required in a matured regulated market.
Topics to be Discussed Include:Overview of the registration procedure and approval process for both generics and biosimilars in the USCritical requirements for a submission for clinical developmentKey inputs and critical success factors for dossier content and preparing for submissionCurrent guidelines under discussion and variation submissions for dossier life cycle management
About Your Workshop Leader
Prior to joining PharmaNet in 2004 and then PPD in 2012, Dr Wu had worked at FDA CDER for 12 plus years, with the last position as DeputyDivision Director, Division of New Drug Chemistry II. His career at FDA included extensive experience in biotechnological/biological productsin both technical and regulatory science. He also represented FDA as a member of ICH Expert Working Groups for both Q5E (Comparability) andCTD-Q (Common Technical Document-Quality) and worked on many domestic and ICH guidances for biotechnology products. Dr. Wu also servedas Chairman of CDER Protein Drug Products Technical Committee, and Follow-on Growth Hormone and Insulin Working Group responsible foran unpublished scientific and regulatory guidance which eventually was used as the basis for approval of Sandoz’s Omnitrope by FDA. He was
also appointed as a member of FDA Follow-on Biologic Working Group and Ad Hoc Reviewer with the USP Biotechnology Committee.
About Your Workshop Leaders
Reinhard Berger, Senior Expert, Federal Office forSafety in Healthcare, Austrian Medicines andMedical Device Agency (AGES), Chairman,Compliance and Enforcement Group (COEN) of theEuropean Commission, AustriaDr Reinhard Berger has over 20 years of experience in
regulatory affairs and is currently a Senior Expert with the Austrian FederalOffice for Safety in Health Care in the Austrian Medicines and Medical DeviceAgency. He has been with the agency since it was founded in 2006 and beforethat he has also gained experienced in the medical device industry. Dr Bergerholds a PhD in Physics from the University of Innsbruck, Institute for AppliedPhysics. He was also recently appointed the Chair of the Compliance andEnforcement Working Group (COEN) in 2012 which underlines his well-recognized position and expertise.
Prof. Jack Wong has over 19 years of Regulatory, Clinical Trialand Pharmacovigilance experience in Asia with good knowledge in the fieldof Medical Devices, Pharmaceuticals, Nutritional, Consumer Healthcare andBiological products. Externally, playing a leading role among all the RegionalRegulatory professionals in AHWP (Asian Harmonization Working Party), andwas invited to provide regulatory training to local universities and industryorganizations. Prof Wong is also very active in ASEAN, APEC, ISO and WHOprojects. In his professional career, Prof Wong developed the First Asia RegulatoryAffairs Certificate course since 2007 with more than 1500 students in alumni.He is also the founder of ARPA (Asia Regulatory Professional Associations) since2010 with more than 1600 members and Asia GRP (Good Regulatory Practice)Research Centre since 2011 with more than 10 companies supporting. His isthe author of First Asia Regulatory Book in Asia (Handbook of Medical DeviceRegulatory Affairs in Asia) and the book was launched in May 2013.
IBCLIFE SCIENCES
PARKROYAL onBeach Road,
Singapore
26-29 August 2014
To check out our tailored sponsorshipsolutions, please contact:Yvonne Leong
Business Development ManagerTel: +65 6508 2489
Email: [email protected]
REGISTER TODAY! +65 6508 2401 [email protected] www.pharmaconasia.com
Asia holds many opportunities in the global pharmaceutical market. However, in orderto tap into this potential, challenges such as opaque, complex and evolving regulatoryguidelines, need to be addressed in order to be successful.
IBC’s 7th Annual Pharmaceutical Regulatory Affairs Asia Conference is the longeststanding regulatory event in the region. By attending this conference, you will no doubtgo home with extensive knowledge on the different regulatory trends, initiatives andon the ground, practical experience for getting drug approvals in Asia.
Key regulatory trends, perspectives and their impact on R&D
Opportunities and requirements for multi-regional clinical trials(MRCT) and bridging studies and waivers in Asia
Post approval variations and its requirements in ensuring quality and safety
Formulating a global regulatory strategy for efficient global product access
Medical device regulations and clinical trials
Topics Not To Be Missed!NEW
Part of:
SPONSORSHIP & EXHIBITION OPPORTUNITIESRAISE awareness of your products and services to regional and international pharmaceuticalregulatory professionals!✔ Stand out from the competition with this branding opportunity✔ Meet and develop new client relationships and also affirm existing ones with your presence
at this event✔ Launching a new regulatory service? Ensure market awareness by showcasing at this event✔ Raise and maintain your corporate profile edge with logo placement
Who Should Attend
■ Regulatory Authorities &Pharmaceutical Companies70%
■ Medical Device Companies10%
■ CROs & Research Institutes15%
■ Legal / Consultants / ServiceProviders 5%
■ Singapore 50%
■ Malaysia 15%
■ Indonesia / Thailand 10%
■ Rest of South East Asia 5%
■ North Asia 10%
■ US / Europe 5%
■ Australia / New Zealand 5%
WHO SHOULD ATTEND?• Head of Medical Affairs• Medical Affairs Directors• MSLs• Chief Medical Officer• Scientific Directors• Medical Directors• Medical and Scientific Affairs Executives
IBCLIFE SCIENCES 4 Successful Events Under 1 Roof!
26 - 29 AUGUST 2014 | PARKROYAL ON BEACH ROAD, SINGAPORE
What is PharmaCon?The Pharmaceutical Congress Asia (PharmaCon) is the leading annual event that brings together Government, pharmaceutical companies andsuppliers in Asia across:
4 Conferences 10 Workshops 4 Days of value-packed information Hours of networking opportunities
The dynamic program and networking platform aims to enable companies to develop strong partnerships, drive innovation and growth, aswell as winning products and services, in Asia’s growing pharmaceutical industry.
Asia’s premier Pharma R&D conference is designedfor professionals in the pharmaceutical R&D sectorto find out the latest investment, partnership andcollaboration opportunities, challenges facing drugdiscovery and clinical development and how toimprove R&D innovation and productivity in Asia.
WHO SHOULD ATTEND?Senior level professionals from:
Designed for regulatory professionals in thepharmaceutical industry to come together to discusseffective regulatory strategies for product accessinto Asia and also globally as well as to gain clarityon the complex and ever changing regulations inthe region.
WHO SHOULD ATTEND?Professionals dealing with:• Global/Regional Regulatory Affairs• Regulatory Compliance• Regulatory Submissions & Publishing• Pharmacovigilance• Market Access
Designed for senior executives from marketing inprescription and consumer health sectors, theconference pinpoints key success factors instrategizing pricing, distribution, advertising &promotion and product differentiation strategy inthis competitive market. This event is Asia’s one andonly platform to provide updated and in-depthevaluation on marketing strategies in thepharmaceutical industry.
WHO SHOULD ATTEND?
• CEO• Chief Marketing Officer• President/Managing Director/Vice
President of Asia• Country Manager• Regional Marketing Director• Head of Corporate Planning• Head of Commercialization• Head of Marketing & Sales• Head of Market Access• Head of Business Development
• Head of Multi-Channel Marketing• Head of Digital Marketing• Head of Product Development• Head of Packaging and Labeling• Head of Procurement & Sourcing• Head of Compliance
MEDICAL AFFAIRS FORUM ASIA is the region’slongest running medical affairs forum where bestpractices are shared and common issues with like-minded peers are discussed. This event will bringinsights on how to be more effective in enhancingyour company’s scientific reputation andcommunicating the value of your products.
• R&D• Drug Discovery• Clinical Trial and
Development• Business Development• Partnerships & Licensing
• Strategic AllianceManagement
• Strategy & PortfolioManagement
• Investment• Mergers & Acquisitions
REGISTER TODAY! +65 6508 2401 [email protected] www.pharmaconasia.com
ENJOY SUBSTANTIAL SAVINGS WITHOUR MULTIPLE BOOKING DISCOUNT!
REGISTER NOW! FAX BACK TO +65 6508 2407
HOTEL INFORMATION
DATA PROTECTION
PAYMENT TERMS
CANCELLATIONS / SUBSTITUTION
IMPORTANT NOTE
6 EASY WAYS TO REGISTER
Customer Service Hotline+65 6508 2401
Fax+65 6508 2407
Webwww.pharmaconasia.com
❑ Yes! I/We will attend the 7th Annual Pharmaceutical Regulatory Affairs Asia | 26 – 29 August 2014, ParkRoyal on Beach Road, Singapore
REG
NO. 2
0010
8203
N
7th Annual Pharmaceutical Regulatory Affairs Asia
❑ I would like to purchase the conference presentations at SGD1000 + GST (SGD1070) per log in.
RESERVE YOUR PLACE TODAY!
CREDIT CARD PAYMENTSThe best way to pay by credit card is through our secure on-line registration process, simply log on to the website atwww.pharmaconasia.com and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name anddetails and our Customer Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictestconfidence, please do not send payment details by email.
Credit card contact: Department:
Direct phone number: Email:
P46247
Payment Method (Please tick:) ❑ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd❑ I am paying by bank transfer (copy attached)❑ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
Payment must be received 10 business days prior to the event. Totake advantage of discounts with an expiry date, registration andpayment must be received by the cut-off date.• Payment by bankers draft or cheque in S$ or US$ should be
made in favour of “IBC Asia (S) Pte Ltd” and mailed to:IBC Asia (S) Pte Ltdc/o Informa Regional Business Services111 Somerset Road, TripleOne Somerset #10-06Singapore 238164Attn: The Accounts Receivable Team
• Payment by bank transfer in S$ or US$ made payable to:IBC Asia (S) Pte LtdA/C No.:147-059513-001 (S$)A/C No.:260-457866-178 (US$)The Hongkong and Shanghai Banking Corporation Limited21 Collyer Quay, HSBC BuildingSingapore 049320Bank Swift Code: HSBCSGSGBank Code: 7232
• Payment by Credit Card (AMEX, VISA or MasterCard).The best way to pay by credit card is through our secure portalbuilt into the website. To pay by phone please indicate thecontact name and details below and our Customer ServicesTeam will call within 24 hours to take payment. Please do notsend credit card information by email.
SAVE WITH THEEARLY BIRD &
SPECIAL RATES!
The personal information entered during your registration/order, orprovided by you, will be held on a database and may be sharedwith companies in the Informa Group in the UK and internationally.Occasionally, your details may be obtained from or shared withexternal companies who wish to communicate with you offersrelated to your business activities. If you do not wish your detailsto be used for this purpose, please contact our Database Departmentat Email: [email protected], Tel: +65 6508 2400 or Fax:+65 6508 2408.
Should you be unable to attend, a substitute delegate is welcomeat no extra charge. Cancellations must be received in writing atleast 10 business days before the start of the event, to receive arefund less 10% processing fee per registration. The companyregrets that no refund will be made available for cancellationnotifications received less than 10 business days before the event.
Please quote the name of the delegate, event title and invoicenumber on the advice when remitting payment. Bank charges areto be deducted from participating organisations own accounts.Please fax your payment details (copy of remittance advice, chequeor draft to +65 6508 2407).Attendance will only be permitted upon receipt of full payment.Participants wishing to register at the door are responsible to ensureall details are as published. IBC assumes no further liability orobligation, beyond the refund of the paid registration fee, in theevent of postponement or cancellation by IBC.
MAIL the attached registration form with yourcheque to IBC Asia (S) Pte Ltdc/o Informa Regional Business Services111 Somerset Road, TripleOne Somerset#10-06, Singapore 238164
Scan the QR Codewith your smartphoneand register today
Early Bird RateRegister & pay on orbefore 20 Jun 2014
FEE PER DELEGATESpecial Rate
Register & pay on orbefore 18 Jul 2014
Group Rate(3 or more delegates)
Normal RateRegister & pay after
18 Jul 2014
❑ 2 Day Conference only
SGD 3,895 SGD 4,095 SGD 4,295 SGD 3,795❑ 4 Day Package: 2 Day Conference +All Workshops
GROUP BONUS – Register 3 Delegates from the same company and the 4th Delegate attends FREE!
SGD 2,595 SGD 2,795 SGD 2,995 SGD 2,495
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time. Fee statedis the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.• Registration fees are subject to the prevailing government tax
Who is Head of your Department?Who is Head of Training?
Company InformationCompany Name:
Address:
Main Business/Activity:
Postal Code:
Please photocopy for additional delegates
FREE
GROUP DISCOUNT
Delegate 1 DetailsName: Dr/Mr/MsJob Title:DepartmentTel:Mobile No.:Email:
Delegate 2 DetailsName: Dr/Mr/MsJob Title:DepartmentTel:Mobile No.:Email:
Delegate 3 DetailsName: Dr/Mr/MsJob Title:DepartmentTel:Mobile No.:Email:
Delegate 4 DetailsName: Dr/Mr/MsJob Title:DepartmentTel:Mobile No.:Email:
SGD 3,295 SGD 3,495 SGD 3,695 SGD 3,195
PARKROYAL on Beach Road7500 Beach Road, Singapore 199591Hotel mainline: +65 6505 5666Contact Person: Teo Hui LingTel: +65 6505 5696Email: [email protected]
❑ 3 Day Package: 2 Day Conference +❑ Pre-Conference Workshop OR❑ Post-Conference Workshop
4 Successful Events Under 1 Roof
180+ Attendees to Network With
4+ Days of Expert Knowledge Sharing
80+ Expert PharmaceuticalStakeholders & Key Decision Makers
15+ Interactive Formats to Get To KnowYour Peers & Customers
1 Joint Exhibition Area
Part of:
